MX
MXCT.O
—
NASDAQ
Advanced Medical Equipment & Technology
MaxCyte Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
114,6M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-157,1 %
ROE
-26,0 %
Net margin
-135,1 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
8,8k
Day range
$1,08–$1,20
Prev close
$1,08
Open
$1,12
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
MaxCyte Inc is a biotechnology company that develops and commercializes advanced cell engineering systems for the production of cell and gene therapies, primarily serving pharmaceutical and biotechnology companies.
Business. MaxCyte Inc (MXCT.O) is a healthcare services and equipment company operating in the advanced medical equipment and technology industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. MaxCyte is headquartered in the United States and is primarily listed on the NASDAQ exchange.
Classification99 %
SectorHealth Care
Industry groupAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
BUY7 analysts
5 buy2 hold0 sell
Avg 12m price target4,29
Analyst recommendations
7 analysts · consensus BuyBuy5
Hold2
Sell0
12-month price target
4,29
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
7 analysts · indicative
Ownership→
BlackRock Institutional Trust Company, N.A.
largest disclosed fund holder
Profitability→
-26,0 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to MXCT.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
MaxCyte Inc (MXCT.O) is a healthcare services and equipment company operating in the advanced medical equipment and technology industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. MaxCyte is headquartered in the United States and is primarily listed on the NASDAQ exchange.
Classification99 %
SectorHealth Care
Industry groupAdvanced Medical Equipment & Technology
AI synthesis
GENERATEDMaxCyte operates with a strong liquidity position, as evidenced by a current ratio of 8.3 and cash and equivalents of $20.07 million. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. However, the company has negative operating and net income, with operating income of -$51.9 million and net income of -$44.6 million, which suggests ongoing financial challenges.
The company's profitability metrics are underperforming relative to industry norms. Return on equity (ROE) is -26.02%, and return on assets (ROA) is -22.04%, both significantly below the industry median for Advanced Medical Equipment & Technology. Gross profit of $26.8 million on revenue of $33.03 million indicates a gross margin of approximately 81.2%, which is relatively high but insufficient to offset the company's operating losses.
MaxCyte's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic breakdown provided. The company's exposure to a single business model increases its vulnerability to market shifts in the cell and gene therapy space. No material geographic diversification is reported, and the company's revenue is not segmented by region.
The company's growth trajectory is mixed. Revenue for the latest period is $33.03 million, but the outlook for the current fiscal year is not provided. Analysts have assigned a mean price target of $4.29, with a median of $5.00, suggesting potential upside from the current market price of $1.09. However, the company's negative operating cash flow of -$34.41 million and free cash flow of -$42.06 million indicate ongoing cash burn.
Risk factors include the company's reliance on a narrow product portfolio and the high costs associated with R&D in the biotechnology sector. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative net income and cash flow suggest potential future dilution if the company needs to raise additional capital.
Recent events include the publication of financial results and analyst estimates. The company has a strong buy recommendation from three analysts, with a mean recommendation of 1.86. No recent filings or transcripts have been disclosed that would indicate significant operational or strategic changes.
Key takeaways
- MaxCyte has a strong liquidity position with a current ratio of 8.3 and no long-term debt.
- The company's profitability metrics are underperforming, with ROE and ROA at -26.02% and -22.04%, respectively.
- Analysts have a generally positive outlook, with a mean price target of $4.29 and a median of $5.00.
- The company's revenue is concentrated in a single business segment, increasing its exposure to market volatility.
- MaxCyte's negative operating and free cash flows indicate ongoing financial challenges and potential future dilution.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$1,07
Market cap
$116.8M
Enterprise valueⓘ
$96.7M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
0.7x
P / Tangible bookⓘ
0.7x
Tangible book
$171.5M
Net cashⓘ
$20.1M
Current ratioⓘ
8.3
Debt / equityⓘ
0.0
ROAⓘ
-22.0%
ROEⓘ
-26.0%
Cash conversionⓘ
77.0%
CapEx / revenueⓘ
-5.3%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships5 disclosed relationships · 2 types · extracted from filings & disclosures
Partners3
Imugene LtdIMU.AXPartner95%Source ↗
Precision Biosciences IncDTIL.OPartner95%Source ↗
Tg Therapeutics IncTGTX.OPartner95%Source ↗
Subsidiaries2
EX21:950830c4a54fEX21:950830c4a54fSubsidiarie97%
EX21:e4594c2d6fcdEX21:e4594c2d6fcdSubsidiarie97%
Supply chain
Vendors → MXCT ↔ Partners → Customers · click any node to drill
3 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
Peer comparison8 peers · vs MXCT · multiples and returns
TM
TMO—
Thermo Fisher Scientific Inc
$574,03
214,1B USDP/E
29,4x
— vs self
Div yield
0,3 %
— vs self
ROE
12,9 %
+38,9 vs self
DH
DHR—
Danaher Corp
$197,50
140,1B USDP/E
38,2x
— vs self
Div yield
—
— vs self
ROE
6,9 %
+32,9 vs self
GE
GEHC—
GE HEALTHCARE TECHNOLOGIES INC.
$69,72
31,9B USDP/E
13,6x
— vs self
Div yield
0,2 %
— vs self
ROE
19,5 %
+45,6 vs self
PH
PHG—
PHG
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BS
BSX—
Boston Scientific Corp
$48,54
72,6B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
IS
ISRG—
INTUITIVE SURGICAL, INC.
$376,00
133,2B USDP/E
287,7x
— vs self
Div yield
—
— vs self
ROE
3,6 %
+29,6 vs self
A
A—
Agilent Technologies Inc
$139,80
39,6B USDP/E
29,0x
— vs self
Div yield
0,8 %
— vs self
ROE
19,3 %
+45,4 vs self
EW
EW—
Edwards Lifesciences Corp
$88,82
51,6B USDP/E
44,3x
— vs self
Div yield
—
— vs self
ROE
10,4 %
+36,4 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,27
Predicted surprise
+0,00
Beat probability
45 %
Analysts
7
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,27 |
| Revenue | —no estimate | —no estimate | 30,8M USD |
| Operating income | —no estimate | —no estimate | -35,9M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution7 analysts
Strong buy3
Buy2
Hold2
Sell0
Strong sell0
12-month price target$4,29 · Median $5,00
Low $2,43High $5,00
Operating income · consensus-35,9M USD
EPS surprise
−45,4 %
reported vs consensus · miss
Revenue surprise
+7,1 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$2,43
Mean$4,29
Median$5,00
High$5,00
Spot$1,07
+300.6 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-157,1 %Bottom quartile
Net Margin-135,1 %Below median
ROE-26,0 %Below median
Capex / Rev-5,3 %Below median
D/E0,00Above median
Cash Conv0,77Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 1 371 632 sh10 grants10 insiders
- Director · Stock Option (right to buy) → Common StockAcquired 49 579 @ $1,13grant · 2026-06-17
- Director · Stock Option (right to buy) → Common StockAcquired 49 579 @ $1,13grant · 2026-06-17
- Director · Stock Option (right to buy) → Common StockAcquired 49 579 @ $1,13grant · 2026-06-17
- Director · Stock Option (right to buy) → Common StockAcquired 49 579 @ $1,13grant · 2026-06-17
- Director · Stock Option (right to buy) → Common StockAcquired 49 579 @ $1,13grant · 2026-06-17
- Director · Stock Option (right to buy) → Common StockAcquired 49 579 @ $1,13grant · 2026-06-17
- Director · Stock Option (right to buy) → Common StockAcquired 49 579 @ $1,13grant · 2026-06-17
- Director · Stock Option (right to buy) → Common StockAcquired 49 579 @ $1,13grant · 2026-06-17
- Chief Financial Officer · Employee Stock Option (right to buy) → Common StockAcquired 375 000 @ $0,68grant · 2026-03-30
- Director, President and CEO · Employee Stock Option (right to buy) → Common StockAcquired 600 000 @ $0,68grant · 2026-03-27
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
Source documents
- MaxCyte Inc Market data — financials · 2026-05-28
- MaxCyte Inc Market data — analyst estimates · 2026-05-28
- MaxCyte Inc Market data — ESG · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,00 %$32M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2025-12-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Maher MasoudPresident, Chief Executive Officer, Director
Insider activity
Net buying5 buys · 1 sellsnet $472K11 insiders · last 365d
- Director · Common StockOther 30 421 · 2026-06-17
- Director · Common StockOther 30 421 · 2026-06-17
- Director · Common StockOther 30 421 · 2026-06-17
- Director · Common StockOther 30 421 · 2026-06-17
- Director · Common StockOther 30 421 · 2026-06-17
- Director · Common StockOther 30 421 · 2026-06-17
- Director · Common StockOther 30 421 · 2026-06-17
- Director · Common StockOther 30 421 · 2026-06-17
- Chief Financial Officer · Common StockOther 187 500 · 2026-04-15
- Director, President and CEO · Common StockOther 300 000 · 2026-03-27
- CHIEF FINANCIAL OFFICER · Common StockSold 10 142 @ $0,81$8K · 2026-03-17
- CHIEF FINANCIAL OFFICER · Common StockBought 50 000 @ $1,29$64K · 2025-08-13
- Director, President and CEO · Common StockBought 75 000 @ $1,37$103K · 2025-08-13
- Director · Common StockBought 100 000 @ $1,37$137K · 2025-08-13
- Director · Common StockBought 80 000 @ $1,39$111K · 2025-08-13
- Director · Common StockBought 50 000 @ $1,29$64K · 2025-08-13
Short positioning
1.4Mshares short-7.2% vs prior
1.22days to cover
9.7%short of daily vol
1.1Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
MXCT.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartnersSubsidiaries
Evidence & claims
From filings & derived data- Current ratio (FY 2025-12-31): 8.30xDerived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -1.4%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -16.9%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -7.7%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -14.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -7.7%Derived (calculated)
- Net margin (FY 2025-12-31): -135.1%Derived (calculated)
- Gross margin (FY 2025-12-31): 81.2%Derived (calculated)
- Return on equity (FY 2025-12-31): -26.0%Derived (calculated)
- Return on assets (FY 2025-12-31): -22.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -15.4%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -12.4%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -24.6%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -8.7%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -6.6%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -15.0%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -28.0%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 7.1%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -6.3%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.18xDerived (calculated)
- Current assets (annual): USD 118.37MSEC XBRL filing
- Total assets (annual): USD 202.51MSEC XBRL filing
- Revenue (annual): USD 33.03MSEC XBRL filing
- Shares outstanding (annual): 106.79MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-17 00:00 UTCINSIDER16 insider transactions — 2026-06 8 derivative
2026-06-17INSIDERBALTHROP PATRICK J transacted 30.4k sh — Director
2026-06-17INSIDERJohnston John Joseph transacted 30.4k sh — Director
2026-06-17INSIDERHemrajani Rekha transacted 30.4k sh — Director
2026-06-17INSIDERErck Stanley C transacted 30.4k sh — Director
2026-06-17INSIDERDOUGLAS RICHARD transacted 30.4k sh — Director
2026-06-17INSIDERCollins Cynthia transacted 30.4k sh — Director
2026-06-17INSIDERBrooke William W transacted 30.4k sh — Director
2026-06-17INSIDERAl-Wakeel Yasir B. transacted 30.4k sh — Director
2026-06-17INSIDERAl-Wakeel Yasir B. acquired 49.6k sh Stock Option (right to buy) — Director
2026-06-17INSIDERBALTHROP PATRICK J acquired 49.6k sh Stock Option (right to buy) — Director
2026-06-17INSIDERBrooke William W acquired 49.6k sh Stock Option (right to buy) — Director
2026-06-17INSIDERCollins Cynthia acquired 49.6k sh Stock Option (right to buy) — Director
2026-06-17INSIDERDOUGLAS RICHARD acquired 49.6k sh Stock Option (right to buy) — Director
2026-06-17INSIDERErck Stanley C acquired 49.6k sh Stock Option (right to buy) — Director
2026-06-17INSIDERHemrajani Rekha acquired 49.6k sh Stock Option (right to buy) — Director
2026-06-17INSIDERJohnston John Joseph acquired 49.6k sh Stock Option (right to buy) — Director
2026-04-15 00:00 UTCINSIDER1 insider transaction — 2026-04
2026-04-15INSIDERAhuja Parmeet transacted 187.5k sh — Chief Financial Officer
2026-03-30 00:00 UTCINSIDER4 insider transactions — 2026-03 2 derivative
2026-03-30INSIDERAhuja Parmeet acquired 375.0k sh Employee Stock Option (right to buy) — Chief Financial Officer
2026-03-27INSIDERMasoud Maher transacted 300.0k sh — Director, President and CEO
2026-03-27INSIDERMasoud Maher acquired 600.0k sh Employee Stock Option (right to buy) — Director, President and CEO
2026-03-17INSIDERSwirsky Douglas J sold 10.1k sh — CHIEF FINANCIAL OFFICER ~$8k
2025-08-13 00:00 UTCINSIDER5 insider transactions — 2025-08 · net buy $480k
2025-08-13INSIDERSwirsky Douglas J bought 50.0k sh — CHIEF FINANCIAL OFFICER ~$64k
Showing the 40 most recent of 45 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage